Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.50 Average Target Price from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $32.50.

GLUE has been the topic of several research reports. JPMorgan Chase & Co. boosted their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Guggenheim cut their target price on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Wells Fargo & Company cut their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Finally, Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th.

Monte Rosa Therapeutics Stock Performance

Monte Rosa Therapeutics stock opened at $18.24 on Wednesday. The firm has a market capitalization of $1.54 billion, a P/E ratio of -12.32 and a beta of 1.60. Monte Rosa Therapeutics has a 1 year low of $4.12 and a 1 year high of $25.77. The business has a 50-day moving average of $18.54 and a 200-day moving average of $18.42.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. Research analysts anticipate that Monte Rosa Therapeutics will post -1.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, COO Jennifer Champoux sold 2,175 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $20.00, for a total value of $43,500.00. Following the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,247,420. This represents a 3.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Philip Nickson sold 5,845 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the transaction, the insider directly owned 55,000 shares in the company, valued at approximately $972,950. This represents a 9.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GLUE. State Street Corp grew its holdings in Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after buying an additional 1,260,707 shares in the last quarter. MPM Bioimpact LLC acquired a new position in Monte Rosa Therapeutics in the 4th quarter valued at $18,399,000. AQR Capital Management LLC grew its holdings in Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares in the last quarter. Braidwell LP acquired a new position in Monte Rosa Therapeutics in the 4th quarter valued at $14,870,000. Finally, Vestal Point Capital LP acquired a new position in Monte Rosa Therapeutics during the third quarter worth about $5,928,000. 79.96% of the stock is owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.